The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies? Domenico GalatiSerena ZanottaAntonio Pinto Review 01 January 2021 Pages: 1797 - 1809
Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment Samuel S. WidodoRyan A. HutchinsonTheo Mantamadiotis Review 03 January 2021 Pages: 1811 - 1820
Immunologic factors involved in the malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma S. LeenenM. HermensE. M. G. van Esch Review 07 January 2021 Pages: 1821 - 1829
CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration Mingsu ShiYun GuWeijuan Zhang Original Article 03 January 2021 Pages: 1831 - 1840
A study of the possible role of Fab-glycosylated IgG in tumor immunity Qian XuXiaodong DengJiang Gu Original Article 03 January 2021 Pages: 1841 - 1851
APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application Erin L. FilbertPia K. BjörckXiaodong Yang Original Article Open access 03 January 2021 Pages: 1853 - 1865
Evaluation of cytokines in the tumor microenvironment of lung cancer using bronchoalveolar lavage fluid analysis Pascal BezelAlan ValapertiDaniel P. Franzen Original Article Open access 04 January 2021 Pages: 1867 - 1876
Transcriptional regulation of VEGFA expression in T-regulatory cells from breast cancer patients Kirti KajalSayantan BoseGaurisankar Sa Original Article 04 January 2021 Pages: 1877 - 1891
Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms Alexander W. MacFarlane IVHo-Man YeungNamrata Vijayvergia Original Article 04 January 2021 Pages: 1893 - 1906
PD-L1 expression in sebaceous carcinomas Maelle SalibaMuhammad ShaheenIbrahim Khalifeh Original Article 04 January 2021 Pages: 1907 - 1915
Identification of new potential antigen recognized by γδT cells in hepatocellular carcinoma Xueyan XiYang GuoBoyu Du Original Article 05 January 2021 Pages: 1917 - 1927
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis Hong-Ming TsaiMeng-Zhi HanHsin-Yu Kuo Original Article Open access 06 January 2021 Pages: 1929 - 1937
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors Noha Abdel-WahabAdi DiabMaria E. Suarez-Almazor Original Article 07 January 2021 Pages: 1939 - 1949
Run for your life: an integrated virtual tissue platform for incorporating exercise oncology into immunotherapy Josua Aponte SerranoAmit Hagar Original Article 08 January 2021 Pages: 1951 - 1964
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma Pedro RochaRuth SalazarLuisa Maren Solis Original Article Open access 08 January 2021 Pages: 1965 - 1976
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma Pedro RochaRuth SalazarLuisa Maren Solis Correction Open access 09 March 2021 Pages: 1977 - 1978
Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL Yue TanJing PanXiaoming Feng Original Article 08 January 2021 Pages: 1979 - 1993
Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values A. Reum KimKyu Sung ChoiChul-Kee Park Original Article 08 January 2021 Pages: 1995 - 2008
Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival Takao KamaiToshiki KijimaKen-Ichiro Yoshida Original Article Open access 08 January 2021 Pages: 2009 - 2021
Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study Philippe ThuillierClaire JolyNathalie Roudaut Original Article 09 January 2021 Pages: 2023 - 2033
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape Seung Geun SongSehui KimDoo Hyun Chung Original Article 09 January 2021 Pages: 2035 - 2048
A template to quantify the location and density of CD3 + and CD8 + tumor-infiltrating lymphocytes in colon cancer by digital pathology on whole slides for an objective, standardized immune score assessment Dordi LeaMartin WatsonKjetil Søreide Original Article Open access 13 January 2021 Pages: 2049 - 2057
CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors Huanpeng ChenFengjiao WeiZhaofeng Huang Original Article 13 January 2021 Pages: 2059 - 2071
Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy Minhui ChenCraig M. BrackettKaterina V. Gurova Original Article 13 January 2021 Pages: 2073 - 2086
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma Valerie GlutschHermann KneitzBastian Schilling Research Report Open access 13 January 2021 Pages: 2087 - 2093
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients Elliot NaidusJerome BouquetLi Zhang Research Report Open access 09 January 2021 Pages: 2095 - 2102